ContextVision AB (CONTX) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of ContextVision AB NOK 0.93, price NOK 5.20, upside -82.1%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ContextVision AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 2.84 – kr 25.95 · fair‑value band kr 0.9200 – kr 0.9300 · the kr 5.20 price screens above the kr 0.9300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow ContextVision in your weekly email
Every Wednesday you see whether ContextVision is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ContextVision AB (publ), a software company, provides image analysis and imaging for medical systems in South Korea, China, Japan, the United States, and internationally.
Show more
ContextVision AB (publ), a software company, provides image analysis and imaging for medical systems in South Korea, China, Japan, the United States, and internationally. The company offers image quality solutions for ultrasound, as well as its Rivent platform comprising Rivent, a 2D image enhancement; Rivent Plus, a premium 2D image enhancement product; Rivent 3D, a solution for improving image quality of 3D ultrasound; and Rivent Mobile, a 2D image enhancement for handheld devices for diagnostics in various fields, including radiology, cardiology, women's health, veterinary medicine, and point of-care applications. It also provides Altumira platform, which features scatter correction and improves radiography by enabling radiation dose reduction while enhancing image quality, such as Altumira for static applications; and Altumira Plus for dynamic applications. In addition, the company offers image quality solutions for MRI including GOPView MRI2Plus for the requirements of each application, sequence type, and protocol; and implementation projects, software updates, and upgrades and product support services. It has a strategic clinical development partnership with the University of Washington to identify a multiparametric biomarker for the screening and staging of the liver disease MASLD; and research partnership with AMRA Medical. ContextVision AB (publ) was incorporated in 1989 and is headquartered in Stockholm, Sweden.
Stock analysis
ContextVision AB (CONTX) currently trades at kr 5.20, while our model-based Fair Value estimate is kr 0.9300, implying the stock looks roughly 459.3% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 1.09 per share, and 0 of the 22 models we run sit above the kr 5.20 price.
Bear case: the Earnings-Based group reads lowest at kr 0.1900, and 22 of the 22 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 0.9200 (bear) to kr 0.9300 (bull), the price of kr 5.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
ContextVision AB reported revenue of 110M SEK in FY2025 versus 98.1M SEK in FY2021, a compound +3.0%/yr. Reported net income was 787K SEK in FY2025.
Key figures
Market cap 402M NOK (≈ $42.2M) · P/E ratio 86.7 · P/S ratio 0.62 · EPS (TTM) kr 0.0600 · Net margin 0.7% · Return on equity 5.2% · Return on assets (EBIT) 28.9% · Revenue (TTM) 109M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 83% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −82%, CONTX screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (kr 0.0500 to kr 2.34). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear kr 0.9200Fair Value kr 0.9300Bull kr 0.9300
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (kr 0.0439 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−15.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Start year 2020 (pandemic). Over 10 years: +4.3% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−39.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−39.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−40% vs −17%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 0%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 134 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−82% · Bottom 25%
Profitability
Return on equity (TTM)5% · Above median
Return on assets1% · Above median
Net margin (TTM)4% · Above median
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth9% · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/E (TTM)86.7× · Priciest 25%
P/B4.55× · Priciest 25%
P/S (TTM)3.86× · Pricier than median
P/FCF209.1× · Priciest 25%
EV/EBITDA74.7× · Priciest 25%
PEG4.07× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 3
FUTURE (revenue growth)46· sector 34
PAST (return on equity)21· sector 5
HEALTH (low debt)0· sector 98
DIVIDEND (yield)0· sector 48
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ContextVision AB Fair Value". https://www.fairvalue-calculator.com/stock/CONTX
Frequently asked questions
Is ContextVision AB (CONTX) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 0.9300 versus a price of kr 5.20, about −82% upside (overvalued).
What is the fair value of CONTX?
Our model-based fair value for ContextVision AB is kr 0.9300 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 5.20.
What is the quality score of CONTX?
ContextVision AB has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ContextVision AB (CONTX)?
Our model-based price target is the fair value of kr 0.9300 (as of Sep 24, 2026) from 22 valuation models. Cautious scenario kr 0.9200, optimistic scenario kr 0.9300. It is a calculation from audited fundamentals, not an analyst target.
What is the ContextVision AB stock forecast for 2026?
Our models put fair value at kr 0.9300, about −82% upside versus a price of kr 5.20 (overvalued). Cautious scenario kr 0.9200, optimistic scenario kr 0.9300. The calculation is refreshed regularly with new filings.
What is the revenue of ContextVision AB (CONTX)?
ContextVision AB reported trailing-twelve-month revenue of about 109M SEK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of ContextVision AB (CONTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ContextVision AB it is kr 0.9300 per share (as of Sep 24, 2026), against a price of kr 5.20. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is ContextVision AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CONTX trades above its calculated fair value: price kr 5.20, fair value kr 0.9300, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CONTX?
No. The price is what the market pays today (kr 5.20); the fair value is what the company's own numbers justify (kr 0.9300). For ContextVision AB the two are kr 4.27 per share apart. That gap is exactly why we show both numbers side by side.
How much is ContextVision AB worth?
The market values ContextVision AB at about 402M NOK (market capitalisation, as of Sep 24, 2026). Per share that is kr 5.20; our models calculate a fair value of kr 0.9300 per share.
What do the bullish and bearish scenarios say about CONTX?
Our models span a range for ContextVision AB: cautious scenario kr 0.9200, base kr 0.9300, optimistic kr 0.9300 per share (as of Sep 24, 2026, price kr 5.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CONTX?
ContextVision AB trades at a price-to-earnings ratio of 86.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 0.9300 is built from several models across several years. Other multiples: PEG 4.1, P/B 4.6, P/S 3.9, EV/EBITDA 74.7.
What is the PEG ratio of CONTX?
The PEG ratio of ContextVision AB is 4.07 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of ContextVision AB (CONTX)?
Balance-sheet figures for ContextVision AB (as of Sep 24, 2026): return on equity 5.2%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is CONTX from its 52-week high?
ContextVision AB trades at kr 5.20, at its 52-week high of kr 5.20 and 83% above the low of kr 2.84 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.9300 is for.
Which stocks are comparable to ContextVision AB?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ContextVision AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 5.20, calculated fair value kr 0.9300 (−82%), Quality Score 52/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CONTX calculated?
We run ContextVision AB through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.9300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. ContextVision AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ContextVision AB (CONTX)?
The closing price on Sep 24, 2026 was kr 5.20. Our model-based fair value is kr 0.9300, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ContextVision AB right now?
The price sits above even our optimistic bull case (kr 0.9300). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (kr 0.9200 to kr 0.9300), unusually little disagreement for a valuation.
Where does the earnings growth of ContextVision AB (CONTX) come from?
Earnings per share at ContextVision AB grew +20.9 % a year from 2013 to 2024. Broken into its drivers: revenue per share +7.5 %, EBIT margin +12.5 %, tax rate +0.3 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of ContextVision AB
How large is the market capitalisation of ContextVision AB (CONTX)?
The market capitalisation of ContextVision AB is 402M NOK (≈ $42.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ContextVision AB (CONTX)?
The price-to-sales ratio of ContextVision AB is 0.62 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ContextVision AB (CONTX)?
Earnings per share at ContextVision AB are kr 0.0600 (price ÷ EPS = P/E 86.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ContextVision AB (CONTX)?
The net margin of ContextVision AB is 0.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ContextVision AB (CONTX)?
The return on equity (ROE) of ContextVision AB is 5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ContextVision AB (CONTX)?
On an EBIT basis the return on assets of ContextVision AB is 28.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at ContextVision AB (CONTX)?
Revenue at ContextVision AB is growing +9.2% versus a year earlier (3y avg −2.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ContextVision AB (CONTX)?
Earnings per share at ContextVision AB are growing −42.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ContextVision AB (CONTX) generate?
The free cash flow of ContextVision AB is 202K SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ContextVision AB (CONTX) hold?
ContextVision AB holds more cash than debt, 63.9M SEK net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch ContextVision AB in the live analysis
One click puts ContextVision AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
